For patients in the sorafenib group, the most common treatment-related acute toxicity was diarrhea (18.1%), followed by AST/ALT elevation (13.0%), bilirubin elevation (11.7%), skin rash (10.8%), and hand–foot syndrome (7.8%) (Table 3). This evidence concerns the gene GPT and exanthem.